STOCK TITAN

RadNet (RDNT) Form 144 Notice — 14,000 Shares Proposed Sale on Nasdaq

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

RadNet, Inc. (RDNT) Form 144 notice reports a proposed sale of 14,000 common shares, scheduled approximately for 09/16/2025 through The Charles Schwab Corporation on Nasdaq with an aggregate market value of $1,049,860.00. The securities were acquired as a stock award on 01/04/2023 and the filer lists 14,000 shares available for sale against a public float of 76,916,062 shares outstanding. The filing also discloses a sale of 17,000 shares on 08/13/2025 for gross proceeds of $1,161,270.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer. Certain issuer contact fields and the filer relationship to the issuer are not specified in the provided content.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider equity sale via Form 144; sizes are small relative to outstanding shares and appear administrative.

This Form 144 discloses a planned sale of 14,000 common shares (approximate value $1.05 million) and a recent prior sale of 17,000 shares. The shares were granted as a stock award in January 2023. Relative to 76.9 million outstanding shares, these transactions are immaterial to RDNT's equity capitalization. No financial performance, new debt, or material corporate events are disclosed. Absent additional context on insider intent or a larger selling program, the filing is a routine disclosure under Rule 144 rather than a material corporate development.

TL;DR: Disclosure aligns with regulatory requirements; no adverse governance signals apparent from the notice alone.

The filing provides required details: acquisition date (01/04/2023), nature of acquisition (stock award), broker, proposed sale date, and past three-month sales. The seller attests to lack of undisclosed material information. The document omits the filer's stated relationship to the issuer and some issuer contact fields, which are factual gaps but do not change the substantive trading disclosure. From a governance perspective, recurring small-volume insider sales can be routine compensation monetization rather than red flags.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the RDNT Form 144 filed here disclose?

The filing discloses a proposed sale of 14,000 common shares (aggregate market value $1,049,860.00) scheduled around 09/16/2025, and a prior sale of 17,000 shares on 08/13/2025 for $1,161,270.00.

Who is the seller listed in the Form 144 for RDNT?

The document identifies David Jeffery Katz as the seller for the prior sale entry; the filer name/CIK fields in the provided excerpt are not fully populated.

How were the shares acquired that are being sold under this Form 144?

The shares were acquired as a stock award on 01/04/2023, with 14,000 shares shown as the amount to be sold.

Through which broker will the proposed RDNT sale be executed?

The proposed sale lists The Charles Schwab Corporation, 3000 Schwab Way Westlake TX 76262 as the broker and indicates execution on NASDAQ.

How large are these sales relative to RDNT's outstanding shares?

The proposed sale of 14,000 shares and the prior sale of 17,000 compare to 76,916,062 shares outstanding, making them small relative to total equity.
Radnet

NASDAQ:RDNT

RDNT Rankings

RDNT Latest News

RDNT Latest SEC Filings

RDNT Stock Data

5.64B
67.21M
12.73%
94.2%
7.83%
Diagnostics & Research
Services-medical Laboratories
Link
United States
LOS ANGELES